Prelude Therapeutics (PRLD) Stock: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$3.63
0.03 (0.83%)
▲
5d:
+11.35%
30d:
-9.02%
90d:
-6.68%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PRLD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PRLD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $3.63, which is considered oversold relative to its 30-day fair value range of $3.55 to $4.52. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.3) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is showing sideways momentum. Immediate support is located at $3.18, while resistance sits at $3.94.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.20 (+153.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRLD is showing sideways momentum. Immediate support is located at $3.18, while resistance sits at $3.94.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $9.20 (+153.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.55 -
$4.52
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.4% below Wall St target ($9.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.55 -
$4.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.18
Resistance Level
$3.94
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.26
Wall Street Target
$9.20
(+153.4%)
Revenue Growth (YoY)
41.0%
Profit Margin
-269.8%
PE vs Historical
-6.3 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 11:31 PM ET
Data refreshes hourly during market hours. Next update: 12:31 AM
Data refreshes hourly during market hours. Next update: 12:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
